These data suggest that [68Ga]Ga-P137 is a promising PSMA-targeted tracer for detecting prostate cancer lesions with PET and the reported novel PSMA-targeting pharmacophore, Lys-urea-(S)-2-amino-3-(carboxyformamido)propanoic acid is also promising for the design of PSMA-targeted radiotherapeutic agents labeled with β- or α-emitter such as 177Lu and 225Ac. Here, FOLH1 is linked to prostate cancer.